Direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, dabigatran, and edoxaban are substrates of P-glycoprotein (and some also of CYP3A4), so berberine could potentially increase their blood levels
Goal: Present GHK-Cu research dosage, reconstitution, supplies, and measurement context in one consistent protocol
The FDA notes the most severe adverse events include melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and prolonged and painful boners
refer to current batch COA Testing methods: HPLC with UV detection coupled with Mass Spectrometry Fill Weight Confirmation: Net content verification for lot consistency Batch verification: Batch-specific COA available when applicable COA & Batch Verification Each applicable batch is documented with available analytical records to support product identification and quality review
Contact [email protected] promptly and do not use, open, reconstitute, or alter a product that is the subject of a claim